Marconi A M, Paolini C, Buscaglia M, Zerbe G, Battaglia F C, Pardi G
Department of Obstetrics and Gynecology, San Paolo Institute of Biomedical Sciences, University of Milano School of Medicine, Italy.
Obstet Gynecol. 1996 Jun;87(6):937-42. doi: 10.1016/0029-7844(96)00048-8.
To test whether the human fetus accommodates to the increasing glucose requirements of late pregnancy with an increased maternal-fetal glucose concentration gradient and whether there are differences in pregnancies with fetal growth restriction (FGR) according to clinical severity.
Umbilical venous glucose concentration was measured in 77 normal pregnancies (appropriate for gestational age [AGA]) and 42 pregnancies complicated by FGR at the time of fetal blood sampling. In 40 AGA and in all FGR cases, a maternal "arterialized" blood sample was collected simultaneously. Growth-restricted fetuses were subdivided into three groups according to fetal heart rate (FHR) recordings and Doppler measurements of the umbilical artery pulsatility index (PI): group 1 (normal FHR and PI; 12 cases), group 2 (normal FHR, abnormal PI; 17 cases) and group 3 (abnormal FHR and PI; 13 cases).
In normal pregnancies with increasing gestational age, there was a significant decrease (P < .001) of umbilical venous glucose concentration and a significant increase of the maternal-fetal glucose concentration difference (P < .001). In addition, there was a significant relation between fetal and maternal glucose concentrations (P < .001). In FGR pregnancies, the maternal-fetal glucose concentration difference was significantly higher in fetuses of groups 2 and 3 compared with normal pregnancies and FGR pregnancies of group 1.
In human pregnancy, the fetal glucose concentration is a function of both gestational age and the maternal glucose concentration. In FGR pregnancies, as an accommodation of the fetus to a restricted placental size and placental glucose transport capacity, the maternal-fetal glucose concentration difference is increased, and this increase is a function of the clinical severity.
检测人类胎儿是否通过增加母胎葡萄糖浓度梯度来适应妊娠晚期不断增加的葡萄糖需求,以及根据临床严重程度,胎儿生长受限(FGR)妊娠是否存在差异。
在77例正常妊娠(适于胎龄[AGA])和42例合并FGR的妊娠中,于胎儿采血时测量脐静脉葡萄糖浓度。在40例AGA妊娠和所有FGR病例中,同时采集母体“动脉化”血样。根据胎儿心率(FHR)记录和脐动脉搏动指数(PI)的多普勒测量,将生长受限胎儿分为三组:第1组(FHR和PI正常;12例),第2组(FHR正常,PI异常;17例)和第3组(FHR和PI异常;13例)。
在正常妊娠中,随着孕周增加,脐静脉葡萄糖浓度显著降低(P <.001),母胎葡萄糖浓度差异显著增加(P <.001)。此外,胎儿和母体葡萄糖浓度之间存在显著相关性(P <.001)。在FGR妊娠中,与正常妊娠和第1组FGR妊娠相比,第2组和第3组胎儿的母胎葡萄糖浓度差异显著更高。
在人类妊娠中,胎儿葡萄糖浓度是孕周和母体葡萄糖浓度的函数。在FGR妊娠中,作为胎儿对胎盘大小受限和胎盘葡萄糖转运能力受限的一种适应,母胎葡萄糖浓度差异增加,且这种增加是临床严重程度的函数。